NCT05931393

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

Phase 2, Open-label, Single Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.

Detailed description

This is a multi-center, open-label, single cohort, phase II study to assess the efficacy of cabozantinib dose escalation at the time of progression on/after cabozantinib monotherapy. The study will enroll subjects with advanced RCC (defined as locally advanced, unresectable or metastatic) who have disease progression on/after cabozantinib monotherapy in any line of treatment

Conditions

• RCC
• Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Cabozantinib 80 MG	cabozantinib 80mg daily

Timeline

• Start date: 2023-12-20
• Primary completion: 2026-09-01
• Completion: 2028-12-31
• First posted: 2023-07-05
• Last updated: 2025-10-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study